Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HCFA

This article was originally published in The Gray Sheet

Executive Summary

Health Care Financing Administration cancels Oct. 1, 2000 implementation of an age restriction on national coverage for autologous stem cell transplantation (AuSCT) for multiple myeloma. The cut-off at age 77 was to serve as a proxy for predicting who would be susceptible to co-morbidities associated with the procedure; the agency will instead try to identify specific co-morbidities that could endanger patients. In order to be eligible for the procedure, patients must demonstrate adequate cardiac, renal, pulmonary and hepatic function
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013935

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel